Results for
""Emtricitabine""[mesh_terms]

Efficacy and safety of long-acting cabotegravir versus oral tenofovir disoproxil fumarate-emtricitabine as HIV pre-exposure prophylaxis: A systematic review and meta-analysis.

Xiu Chen, Jun Li, Liqiu Kou, Xiaolu Xie, Deqing Wei, Yaling Li

Reviews in medical virology 2023;33(4):e2460

Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial.

Borja Mora-Peris, Michael R Keegan, Sujan Dilly Penchala, Jaime H Vera, Jonathan Underwood, Maryam Khan, Carolina Herrera, Dietmar Fuchs, Adriano Boasso, Saye Khoo, Alan Winston

HIV research & clinical practice 2022;22(6):151-159

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.

Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, Magda Opsomer, Kimberley Brown, Romana Petrovic, Joseph J Eron, Chloe Orkin, Douglas Cunningham, Federico Pulido, Frank A Post, Stéphane De Wit, John Jezorwski

Antiviral research 2020;170():104543

Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data.

Fehmi Tabak, Esra Zerdali, Ozlem Altuntaş, Alper Gunduz, Sibel Bolukcu, Bilgul Mete, Inci Y Nakir, Hayat Kumbasar Karaosmanoglu, Dilek S Yildiz, Meliha Meric Koc, İlyas Dokmetas

International journal of STD & AIDS 2021;32(6):562-569

Genvoya-Associated and Simvastatin-Associated Noninflammatory and Nonautoimmune Myopathy: A Case Report and Literature Review.

Merry Huang, Richard A Prayson, Yuebing Li

Journal of clinical neuromuscular disease 2022;24(2):75-79

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.

Gregory D Huhn, Aimee Wilkin, Cristina Mussini, Christoph D Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh

HIV research & clinical practice 2022;21(6):151-167

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

Michael Miller, Hedy Teppler, Peter Sklar, Edwin DeJesus, Bach-Yen Nguyen, Michael S Saag, Yazdan Yazdanpanah, Mark J DiNubile, Hong Wan, Jeffrey L Lennox, Anthony J Rodgers, Randi Leavitt, Monica L Walker, Jürgen K Rockstroh

Journal of acquired immune deficiency syndromes (1999) 2013;63(1):77-85

Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients.

Edgar Pérez-Barragán, Mónica Fernanda Guevara-Maldonado, Javier Mancilla-Galindo, Ashuin Kammar-García, Alejandro Ortiz-Hernández, José Antonio Mata-Marín, Samantha Pérez-Cavazos

AIDS research and human retroviruses 2023;39(10):511-517

Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.

Carolina Herrera, Jennifer Serwanga, Laura Else, Lebina Limakatso, Daniel Opoka, Andrew S Ssemata, Azure-Dee Pillay, Patricia Namubiru, Thabiso B Seiphetlo, Geoffrey Odoch, Susan Mugaba, Portia Seatlholo, Amara Alieu, Sujan Dilly Penchala, Richard Muhumuza, Berenice Alinde, Stefan Petkov, Kyle O'Hagan, Christian Callebaut, Janet Seeley, Helen Weiss, Saye Khoo, Francesca Chiodi, Clive M Gray, Pontiano Kaleebu, Emily L Webb, Neil Martinson, Julie Fox

EBioMedicine 2023;93():104648

No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up.

Leonardo Calza, Marco Borderi, Vincenzo Colangeli, Aurora Borioni, Simona Coladonato, Bianca Granozzi, Pierluigi Viale

Infectious diseases (London, England) 2020;52(4):249-256

The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.

Roger J Bedimo, Henning Drechsler, Mamta Jain, James Cutrell, Song Zhang, Xilong Li, Irfan Farukhi, Rosinda Castanon, Pablo Tebas, Naim M Maalouf

PloS one 2015;9(8):e106221

A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.

Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle

HIV research & clinical practice 2022;22(5):128-139

Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.

Katherine Gill, Leigh Johnson, Janan Dietrich, Landon Myer, Rebecca Marcus, Melissa Wallace, Tanya Pidwell, Eve Mendel, Lauren Fynn, Kai Jones, Lubbe Wiesner, Catherine Slack, Ann Strode, Hans Spiegel, Sybil Hosek, James Rooney, Glenda Gray, Linda-Gail Bekker

The Lancet. Child & adolescent health 2021;4(12):875-883

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.

José R Santos, María Saumoy, Adrian Curran, Isabel Bravo, Josep M Llibre, Jordi Navarro, Carla Estany, Daniel Podzamczer, Esteban Ribera, Eugènia Negredo, Bonaventura Clotet, Roger Paredes

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016;61(3):403-8